Chiral alpha-aryl amide compound and synthesis method thereof
Through photon-nickel synergistic catalysis technology, chiral α-aryl amide compounds are synthesized from α-hydroxycarboxylic acid compounds, which solves the problem of stereoselective construction in the prior art and the problem of limited application of α-hydroxycarboxylic acid compounds. An efficient and convenient synthesis method is realized.
Patent Information
- Application Number
- CN202411057646.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art is difficult to effectively construct the stereoselectivity of chiral α-arylamide compounds under alkaline conditions, and the application of α-hydroxycarboxylic acid compounds as coupling reagents is limited by the high bond dissociation of carbon-oxygen bonds. able.
By condensing the protected carboxyl groups from the cheap and easy-to-get α-hydroxycarboxylic acid compound in one step, α-hydroxyamide compounds are generated, and the enantioconvergent deoxygenation reduction coupling reaction between α-hydroxyamide and aryl bromine is achieved by photonickel synergistically catalyzing. Synthesis of chiral α-arylamide compounds.
It has achieved efficient and convenient synthesis of chiral α-arylamide compounds, good stereoselectivity, wide source of raw materials, mild reaction conditions, and easy separation and purification of products.
Smart Images

Figure CN118978452A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of organic chemical synthesis, and in particular to a chiral alpha-aryl amide compound and a synthesis method thereof. Background Art
[0002] Chiral α-arylamide compounds are widely present in medicines, pesticides and natural products, and are also an important class of organic synthesis intermediates. Therefore, the development of simple and efficient synthesis methods for enantiomer-enriched α-arylamide compounds has always attracted much attention. However, due to the electron-withdrawing properties of carbonyl and aryl groups, tertiary carbon chiral centers are very prone to racemization under alkaline conditions, so stereoselective construction of chiral centers is a major problem.
[0003] α-Hydroxycarboxylic acid compounds are a ubiquitous biomass resource in nature. Taking lactic acid as an example, dehydroxylation of lactic acid molecules will greatly increase their value in chemical synthesis. However, the carbon-oxygen bond has a high bond dissociation energy, which limits the application of lactic acid as a coupling reagent in the field of chemical synthesis. In 2021, the MacMillan group achieved the deoxyarylation of alkyl alcohols by in situ activation of carbon-oxygen bonds with NHC (N-arylbenzoxazolium salts). The reaction has good versatility for primary, secondary and tertiary alcohols. This scheme provides a good strategy for the dehydroxylation functionalization of α-hydroxycarboxylic acid compounds.
[0004] Based on the above background, the present invention starts from cheap and readily available α-hydroxycarboxylic acid compounds, and generates α-hydroxyamide compounds by protecting the carboxyl group through a simple one-step condensation. Then, the enantioconvergent deoxygenation reduction coupling reaction of α-hydroxyamide and aryl bromide is achieved through photo-nickel synergistic catalysis, and an efficient and convenient method is developed for the synthesis of chiral α-arylamide compounds. Summary of the invention
[0005] The purpose of the present invention is: Based on the above technical problem, the present invention provides a chiral α-aryl amide compound and a synthesis method thereof.
[0006] In order to achieve the above object, the first aspect of the present invention provides a chiral α-aryl amide compound having a structure shown in formula (I):
[0007] Among them, R 1 is a benzyl group or a group having the following structure: R 2 is methyl, ethyl, n-butyl, isobutyl or -CH2CH2NHCbz, R 3 is methyl, isobutyl, methoxy, phenyl, cyano, acetyl or trifluoromethyl.
[0008] The second aspect of the present invention provides a method for preparing a chiral α-aryl amide compound, the method comprising the following steps:
[0009] (1) subjecting the compound represented by formula (I-1) to a first reaction with the compound represented by formula (I-2) to obtain the compound represented by formula (I-3); the conditions of the first reaction at least satisfy the following conditions: a temperature of 100 to 130° C., a time of 6 to 12 hours; and an amount ratio of the compound represented by formula (I-1) to the compound represented by formula (I-2) of 1:1 to 1:1.2;
[0010] (2) In an organic solvent I, a catalyst, a ligand, and Ir[dF(CF3)ppy]2(dtbbpy)PF6 are first mixed to obtain a solution I;
[0011] In the presence of organic solvent II, the compound represented by formula (I-3) and NHC are mixed for a second time, 4-OMe-pyridine is added dropwise, and a third mixing and separation treatment are performed in sequence to obtain solution II;
[0012] (3) subjecting the compound represented by formula (I-4), quinuclidine, phthalimide, the solution I, and the solution II to a second reaction to obtain a compound represented by formula (I);
[0013] R 1 -NH2 formula (I-1),
[0014] Among them, in formula (I), formula (I-1), formula (I-2), formula (I-3), and formula (I-4), R 1 , R 2 , R 3 The definitions are the same as those in claim 1.
[0015] The chiral α-aryl amide compound provided by the present invention is synthesized from α-hydroxyamide as a precursor through photo-nickel coordinated catalysis, the chiral center is located at the α position of the carbonyl, and the preparation method is simple, the raw material source is wide, the reaction conditions are mild, and the product is easy to separate and purify. DETAILED DESCRIPTION
[0016] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0017] In the present invention, in the structural formula of the compound represented by formula (I), the compound represented by formula (I-1) or the compound represented by formula (I-2), "Bn-" represents a benzyl group, "Me-" represents a methyl group, and "i-Bu-" represents an isobutyl group.
[0018] In the ligand, "-Cy" represents a cyclohexyl group.
[0019] As mentioned above, the first aspect of the present invention provides a chiral α-aryl amide compound having a structure shown in formula (I):
[0020] Among them, R 1 is a benzyl group or a group having the following structure: R 2 is methyl, ethyl, n-butyl, isobutyl or -CH2CH2NHCbz, R 3 is methyl, isobutyl, methoxy, phenyl, cyano, acetyl or trifluoromethyl.
[0021] As mentioned above, the second aspect of the present invention provides a method for preparing a chiral α-aryl amide compound, the method comprising the following steps:
[0022] (1) subjecting the compound represented by formula (I-1) to a first reaction with the compound represented by formula (I-2) to obtain the compound represented by formula (I-3); the conditions of the first reaction at least satisfy the following conditions: a temperature of 100 to 130° C., a time of 6 to 12 hours; and an amount ratio of the compound represented by formula (I-1) to the compound represented by formula (I-2) of 1:1 to 1:1.2;
[0023] (2) In an organic solvent I, a catalyst, a ligand, and Ir[dF(CF3)ppy]2(dtbbpy)PF6 are first mixed to obtain a solution I;
[0024] In the presence of organic solvent II, the compound represented by formula (I-3) and NHC are mixed for a second time, 4-OMe-pyridine is added dropwise, and a third mixing and separation treatment are performed in sequence to obtain solution II;
[0025] (3) subjecting the compound represented by formula (I-4), quinuclidine, phthalimide, the solution I, and the solution II to a second reaction to obtain a compound represented by formula (I);
[0026] R 1 -NH2 formula (I-1),
[0027] Among them, in formula (I), formula (I-1), formula (I-2), formula (I-3), and formula (I-4), R 1 , R 2 , R 3 The definitions are the same as those in claim 1.
[0028] In the present invention, Ir[dF(CF3)ppy]2(dtbbpy)PF6 is a photosensitizer, which changes from a ground state to an excited state after being irradiated with light, and plays the role of single-electron oxidation and single-electron reduction in the reaction.
[0029] In the present invention, the ligand and the catalyst (NiBr2·DME) are combined to form a chiral catalyst, which plays a role in controlling the stereoselectivity of the product.
[0030] In the present invention, 4-OMe-pyridine and quinuclidine act as organic bases in solution I and solution II, respectively.
[0031] In the present invention, phthalimide is used as an additive to assist the chiral catalyst in improving the stereoselectivity of the product.
[0032] Preferably, in step (1), in the compound represented by formula (I-1), R 1 It is benzyl.
[0033] Further preferably, in step (1), the R 1 A group having the following structure:
[0034]
[0035] Preferably, in step (1), the method further comprises: after the first reaction and before obtaining the compound represented by the formula (I-3), the temperature is lowered to room temperature, 100 mL of water is added to the product obtained after the first reaction, and extracted three times with ethyl acetate (the amount of ethyl acetate used each time is 30 mL), the organic phase is collected, and the organic phase is dried with an appropriate amount of anhydrous sodium sulfate, filtered, and then placed in a rotary evaporator, dried at 50°C and 400 rpm for 20 minutes, the residue is purified by column chromatography, and then placed in a vacuum double-row tube to remove the solvent and moisture.
[0036] Preferably, in step (2), the organic solvent I is anhydrous trifluoromethylbenzene, the organic solvent II is methyl tert-butyl ether, and the usage ratio of the organic solvent I to the organic solvent II is 1:1.
[0037] Preferably, in step (2), the catalyst is NiBr2·DME, and the amount of the catalyst used is 0.05 mmol relative to 0.50 mmol of the compound represented by formula (I-4).
[0038] More preferably, in step (2), the ligand has the structure shown below:
[0039]
[0040] Preferably, in step (2), the amount of the ligand used is 0.06 mmol relative to 0.50 mmol of the compound represented by formula (I-4).
[0041] Further preferably, in step (2), relative to 0.50 mmol of the compound represented by formula (I-4), the amount of Ir[dF(CF3)ppy]2(dtbbpy)PF6 used is 0.0075 mmol.
[0042] Preferably, in step (2), the amount of NHC used is 0.80 mmol relative to 0.50 mmol of the compound represented by formula (I-4).
[0043] Further preferably, in step (2), the first mixing conditions at least meet the following conditions: sealing, room temperature, and stirring time of 30 minutes.
[0044] Preferably, in step (2), the second mixing conditions at least meet the following requirements: sealing, room temperature, and stirring time of 5 minutes.
[0045] More preferably, in step (2), the third mixing conditions at least meet the following requirements: sealing, room temperature, and stirring time of 30 minutes.
[0046] Preferably, in step (2), the separation treatment is performed by filtering, specifically, filtering out the white precipitate and taking the filtrate.
[0047] Preferably, in step (3), the amount of quinuclidine used is 0.60 mmol relative to 0.50 mmol of the compound represented by formula (I-4).
[0048] Preferably, in step (3), the conditions of the second reaction at least meet the following requirements: sealing, temperature of 0° C., irradiation with a blue LED light, and stirring time of 36 h.
[0049] Further preferably, in step (3), the method further comprises: after the second reaction value and before obtaining the chiral α-aryl amide compound, filtering the product obtained after the second reaction through a silica gel column, taking the filtrate, and washing the vial III, the bottle cap, and the silica gel column with ethyl acetate, combining the eluent and the filtrate, and then concentrating the concentrated solution to obtain the concentrated solution, and separating and purifying the concentrated solution on a silica gel column.
[0050] Preferably, the usage ratio of the compound represented by formula (I-4) to the compound represented by formula (I-3) is 1:1.6.
[0051] The present invention will be described in detail below by way of examples. In the following examples, unless otherwise specified, the raw materials are all commercially available.
[0052] In the following examples, the ligand has a CAS number of 2706576-80-7 and has the structure shown below:
[0053]
[0054] In the following examples, unless otherwise specified, the yield of the chiral α-aryl amide compound is obtained by using a nuclear magnetic resonance spectrometer of Bruker 400 MHz.
[0055] In the following examples, unless otherwise specified, the room temperature is 25±2°C.
[0056] Vial I and Vial II are 4 mL in size and must be dried before use;
[0057] Vial III, specification is 20mL, and must be dried before use;
[0058] Blue LED light, wavelength 455nm, power 30W.
[0059] As mentioned above, the structural formula of the compound represented by formula (I-2) is In the following examples, in the compound represented by formula (I-2), when R 2 is Me, the compound represented by formula (I-2) is denoted as 1a; in the compound represented by formula (I-2), when R 2 It is -CH2CH2NHCbz, and the compound represented by formula (I-2) is denoted as 1b.
[0060] As mentioned above, the structural formula of the compound represented by formula (I-3) is In the following examples, in the compound represented by formula (I-3), when R 1 Bn, R 2 is Me, the compound represented by formula (I-3) is denoted as 2a; in the compound represented by formula (I-3), when R 1 Bn, R 2 is -CH2CH2NHCbz, the compound represented by formula (I-3) is denoted as 2b; in the compound represented by formula (I-3), when R 1 for R 2 is Me, and the compound represented by formula (I-3) is denoted as 2c.
[0061] Example 1
[0062]
[0063] (1) 1a and benzylamine (wherein 1a is 20 mmol, 1.8 g) in a molar ratio of 1:1 are added to a 20 mL pressure tube, without adding any solvent, and the tube is sealed and reacted at 130° C. for 6 h. When the temperature drops to room temperature, 100 mL of water is added thereto, and the mixture is extracted three times with ethyl acetate (each time with 30 mL of ethyl acetate). The organic phase is collected, and the organic phase is dried with an appropriate amount of anhydrous sodium sulfate, filtered, and then placed in a rotary evaporator and dried at 50° C. and 400 rpm for 20 min. The residue is purified by column chromatography and then placed in a vacuum double-row tube to remove the solvent and water to obtain 2a with a purity of >97%.
[0064] (2) In a glove box, 0.05 mmol NiBr2·DME (15.5 mg), 0.06 mmol ligand (34.0 mg), and 0.0075 mmol Ir[dF(CF3)ppy]2(dtbbpy)PF6 (9.0 mg) were added to a vial I equipped with a stirring bar, and then 2.5 mL of anhydrous trifluoromethylbenzene was added. The cap of the vial I was sealed and stirred at room temperature for 30 min to obtain a deep red solution, which was recorded as solution I.
[0065] 0.80 mmol 2a (143.2 mg) and 0.80 mmol NHC (316.5 mg) were added to vial II, and then 2.5 mL methyl tert-butyl ether was added. After mixing, the mixture was stirred at room temperature for 5 min. Then 0.80 mmol 4-OMe-pyridine (81.5 μL) was added dropwise, and the mixture was stirred at room temperature for 30 min (a white solid was precipitated during this period) to obtain a suspension. The suspension was filtered and a uniform colorless solution was taken, which was recorded as solution II.
[0066] (3) In a glove box, 0.50 mmol 1-bromo-4-isobutylbenzene (106.5 mg) and 0.60 mmol quinuclidine (67 mg) were added to vial III, and then 2.5 mL of the solution I and 2.5 mL of the solution II were added to the vial III using a syringe, and 0.02 mmol phthalimide (2.9 mg) was added. The cap of the vial III was sealed, and the vial was transferred to a 0°C EtOH cooling bath and stirred for 5 min. The vial was then irradiated with a blue LED light and stirred for 36 h at 0°C. The vial was filtered through a silica gel column, the filtrate was taken, and the vial III, the cap, and the silica gel column were rinsed with ethyl acetate. The eluent and the filtrate were combined and concentrated to obtain a concentrate, which was separated and purified on a silica gel column (ethyl acetate and petroleum ether in a volume ratio of 1:3) to obtain a chiral α-aryl amide compound, which was recorded as Amide-a.
[0067] Amide-a, white solid. 1 H NMR(400MHz,Chloroform-d)δ7.31–7.24(m,3H),7.24–7.21(m,2H),7.17–7.10(m,4H),5.67(s,1H),4.41(d,J=5.8H z,2H),3.60(q,J=7.2Hz,1H),2.47(d,J=7.2Hz,2H),1.92–1.82(m,1H),1.57(d,J=7.2Hz,3H),0.92(d,J=6.6Hz,6H). 13 C NMR(101MHz,Chloroform-d)δ174.3,140.8,138.5,138.4,129.6,128.6,127.34,127.28,46. 8,45.0,43.5,30.1,22.3,18.4.FT-IR(film):3310,2969,2903,1645,1538,1231,1069,690cm -1 .HRMS(ESI-MS)m / z[M+Na] + Calculate for C 20 H 25 NNaO:318.1828,found:318.1828.[α] 15 D =0.2(c 1.0, CHCl3); 93%ee, from (S)-L1.
[0068] Example 2
[0069]
[0070] (1) 1b and benzylamine (wherein 1b is 10 mmol, 1.5 g) in a molar ratio of 1:1 are added to a 20 mL pressure tube, 5 mL of DMF is added, the tube is sealed, and the reaction is carried out at 100° C. for 6 h. When the temperature drops to room temperature, 100 mL of water is added thereto, and the mixture is extracted three times with ethyl acetate (the amount of ethyl acetate used each time is 30 mL). The organic phase is collected, and the organic phase is dried with an appropriate amount of anhydrous sodium sulfate, filtered, and then placed in a rotary evaporator and dried at 50° C. and 400 rpm for 20 min. The residue is purified by column chromatography and then placed in a vacuum double-row tube to remove the solvent and water to obtain 2b with a purity of >97%.
[0071] (2) In a glove box, 0.05 mmol NiBr2·DME (15.5 mg), 0.06 mmol ligand (34.0 mg), and 0.0075 mmol Ir[dF(CF3)ppy]2(dtbbpy)PF6 (9.0 mg) were added to a vial I equipped with a stirring bar, and then 2.5 mL of anhydrous trifluoromethylbenzene was added. The cap of the vial I was sealed and stirred at room temperature for 30 min to obtain a deep red solution, which was recorded as solution I.
[0072] 0.80 mmol 2b (143.2 mg) and 0.80 mmol NHC (316.5 mg) were added to vial II, and then 2.5 mL methyl tert-butyl ether was added. After mixing, the mixture was stirred at room temperature for 5 min. Then 0.80 mmol 4-OMe-pyridine (81.5 μL) was added dropwise, and the mixture was stirred at room temperature for 30 min (a white solid was precipitated during this period) to obtain a suspension. The suspension was filtered and a uniform colorless solution was taken, which was recorded as solution II.
[0073] (3) In a glove box, 0.50 mmol 1-bromo-4-isobutylbenzene (106.5 mg) and 0.60 mmol quinuclidine (67 mg) were added to vial III, and then 2.5 mL of the solution I and 2.5 mL of the solution II were added to the vial III using a syringe, and 0.02 mmol phthalimide (2.9 mg) was added. The cap of the vial III was sealed, and the mixture was transferred to a 0°C EtOH cooling bath and stirred for 5 min. The mixture was then irradiated with a blue LED light and stirred for 36 h at 0°C. The mixture was filtered through a silica gel column, the filtrate was taken, and the vial III, the cap, and the silica gel column were rinsed with ethyl acetate. The eluent and the filtrate were combined and concentrated to obtain a concentrate, which was separated and purified on a silica gel column (ethyl acetate and petroleum ether in a volume ratio of 1:1) to obtain a chiral α-arylamide compound, which was designated as Amide-b.
[0074] Amide-b, white solid.1 H NMR(400MHz,Chloroform-d)δ7.39–7.28(m,5H),7.28–7.20(m,3H),7.18(d,J=7 .8Hz,2H),7.10(d,J=7.6Hz,4H),5.86(s,1H),5.07(s,2H),4.97(s,1H),4.37(d ,J=5.6Hz,2H),3.42(t,J=7.4Hz,1H),3.27–3.13(m,2H),2.44(d,J=7.2Hz,2H), 2.43–2.35(m,1H),2.03–1.94(m,1H),1.87–1.79(m,1H),0.89(d,J=6.6Hz,6H). 13 C NMR(101MHz,Chloroform-d)δ173.2,156.5,141.1,138.2,136.6,129.7,128.6,128.5,128.1,127.6,127.4,127.3, 66.6,50.4,45.0,43.6,39.6,33.3,30.1,22.3.FT-IR(film):3670,3333,2922,1695,1616,1534,1450,1068,690cm -1 .HRMS(ESI-MS)m / z[M+H]+calcd for C29H36N2O3:459.2642,found:459.2645.[α] 15 D =2.1 (c 1.0, CHCl3); 88%ee, from (S)-L1.
[0075] Example 3
[0076]
[0077] (1) 1a and S(-)-α-phenylethylamine (wherein 1a is 10 mmol, 1.5 g) in a molar ratio of 1:1 are added to a 20 mL pressure tube, without adding any solvent, and the tube is sealed and reacted at 130° C. for 12 h. When the temperature drops to room temperature, 100 mL of water is added thereto, and the mixture is extracted three times with ethyl acetate (each time with 30 mL of ethyl acetate). The organic phase is collected, and the organic phase is dried with an appropriate amount of anhydrous sodium sulfate, filtered, and then placed in a rotary evaporator and dried at 50° C. and 400 rpm for 20 min. The residue is purified by column chromatography and then placed in a vacuum double-row tube to remove the solvent and water to obtain 2c with a purity of >97%.
[0078] (2) In a glove box, 0.05 mmol NiBr2·DME (15.5 mg), 0.06 mmol ligand (34.0 mg), and 0.0075 mmol Ir[dF(CF3)ppy]2(dtbbpy)PF6 (9.0 mg) were added to a vial I equipped with a stirring bar, and then 2.5 mL of anhydrous trifluoromethylbenzene was added. The cap of the vial I was sealed and stirred at room temperature for 30 min to obtain a deep red solution, which was recorded as solution I.
[0079] 0.80 mmol 2c (143.2 mg) and 0.80 mmol NHC (316.5 mg) were added to vial II, and then 2.5 mL methyl tert-butyl ether was added. After mixing, the mixture was stirred at room temperature for 5 min. Then 0.80 mmol 4-OMe-pyridine (81.5 μL) was added dropwise, and the mixture was stirred at room temperature for 30 min (a white solid was precipitated during this period) to obtain a suspension. The suspension was filtered and a uniform colorless solution was taken, which was recorded as solution II.
[0080] (3) In a glove box, 0.50 mmol 1-bromo-4-isobutylbenzene (106.5 mg) and 0.60 mmol quinuclidine (67 mg) were added to vial III, and then 2.5 mL of the solution I and 2.5 mL of the solution II were added to the vial III using a syringe, and 0.02 mmol phthalimide (2.9 mg) was added. The cap of the vial III was sealed, and the vial was transferred to a 0°C EtOH cooling bath and stirred for 5 min. The vial was then irradiated with a blue LED light and stirred for 36 h at 0°C. The vial was filtered through a silica gel column, the filtrate was taken, and the vial III, the cap, and the silica gel column were rinsed with ethyl acetate. The eluent and the filtrate were combined and concentrated to obtain a concentrate, which was separated and purified on a silica gel column (ethyl acetate and petroleum ether in a volume ratio of 1:4) to obtain a chiral α-aryl amide compound, which was recorded as Amide-c.
[0081] Amide-c, white solid. 1 H NMR(600MHz,Chloroform-d)δ7.26–7.18(m,3H),7.18–7.15(m,2H),7.10(d,J=8.1Hz,2H),7.09–7.04(m,2H),5.58(s,1H),5.10–5.04(m,1H ), 3.56 (q, J = 7.2Hz, 1H), 2.46 (d, J = 7.2Hz, 2H), 1.89–1.82 (m, 1H), 1.51 (d, J = 7.2Hz, 3H), 1.39 (d, J = 6.9Hz, 3H), 0.90 (dd, J = 6.6, 1.3Hz, 6H). 13C NMR(151MHz,Chloroform-d)δ173.4,143.3,140.7,138.6,129.6,128.4,127.3,127.0,125.7,48.5 ,46.7,45.0,30.2,22.3,22.3,21.9,18.2.FT-IR(film):3287,2974,2899,1635,1541,1066,696cm -1 .HRMS(ESI-MS)m / z[M+K] + Calculate for C 21 H 27 KNO:348.1724,found:348.1723.[α] 15 D =13.1(c 1.0,CHCl3);95:5dr,from(S)-L1.
[0082] Comparative Example 1
[0083] The chiral α-aryl amide compound was prepared according to the method of Example 1, except that in step (3), the stirring time of the second reaction was 18 h. The remaining steps and parameters were the same as those of Example 1.
[0084] The obtained chiral α-aryl amide compound is denoted as Amide-a-1 and is a white solid.
[0085] Comparative Example 2
[0086] The chiral α-aryl amide compound was prepared according to the method of Example 1, except that in step (2), the same volume of tetrahydrofuran was used instead of methyl tert-butyl ether, and the remaining steps and parameters were the same as in Example 1.
[0087] The obtained chiral α-aryl amide compound is denoted as Amide-a-2 and is a white solid.
[0088] Comparative Example 3
[0089] The chiral α-aryl amide compound was prepared according to the method of Example 1, except that in step (3), sodium acetate was used in the same molar ratio to replace quinuclidine, and the remaining steps and parameters were the same as in Example 1.
[0090] The obtained chiral α-aryl amide compound is denoted as Amide-a-3 and is a white solid.
[0091] The yields of the chiral α-aryl amide compounds prepared in the above examples and comparative examples were calculated, and the results are shown in Table 1.
[0092] Table 1
[0093] Example No. Yield, % Example 1 83 Example 2 89 Example 3 88 Comparative Example 1 67 Comparative Example 2 18 Comparative Example 3 8
[0094] It can be seen from the results in Table 1 that the chiral α-aryl amide compound prepared by the embodiment of the present invention has a higher yield.
[0095] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.
Claims
1. A chiral α-aryl amide compound, characterized in that: The compound has a structure shown in formula (I), Among them, R 1 is a benzyl group or a group having the following structure: R 2 is methyl, ethyl, n-butyl, isobutyl or -CH2CH2NHCbz, R 3 is methyl, isobutyl, methoxy, phenyl, cyano, acetyl or trifluoromethyl.
2. A method for preparing a chiral α-aryl amide compound, characterized in that: The method comprises the following steps: (1) subjecting the compound represented by formula (I-1) to a first reaction with the compound represented by formula (I-2) to obtain the compound represented by formula (I-3); the conditions of the first reaction at least satisfy the following conditions: a temperature of 100 to 130° C., a time of 6 to 12 hours; and an amount ratio of the compound represented by formula (I-1) to the compound represented by formula (I-2) of 1:1 to 1:1.2; (2) In an organic solvent I, a catalyst, a ligand, and Ir[dF(CF3)ppy]2(dtbbpy)PF6 are first mixed to obtain a solution I; In the presence of organic solvent II, the compound represented by formula (I-3) and NHC are mixed for a second time, 4-OMe-pyridine is added dropwise, and a third mixing and separation treatment are performed in sequence to obtain solution II; (3) subjecting the compound represented by formula (I-4), quinuclidine, phthalimide, the solution I, and the solution II to a second reaction to obtain a compound represented by formula (I); Among them, in formula (I), formula (I-1), formula (I-2), formula (I-3), and formula (I-4), R 1 , R 2 , R 3 The definitions are the same as those in claim 1.
3. The method according to claim 2, wherein: In step (1), in the compound represented by formula (I-1), R 1 is benzyl; and / or, the R 1 A group having the following structure:
4. The method according to claim 2 or 3, wherein: In step (2), the organic solvent I is anhydrous trifluoromethylbenzene, the organic solvent II is methyl tert-butyl ether, and the usage ratio of the organic solvent I to the organic solvent II is 1:1; And / or, in step (2), the catalyst is NiBr2·DME, and the amount of the catalyst used is 0.05 mmol relative to 0.50 mmol of the compound represented by formula (I-4); And / or, in step (2), the ligand has the structure shown below: And / or, in step (2), the amount of the ligand used is 0.06 mmol relative to 0.50 mmol of the compound represented by formula (I-4).
5. The method according to claim 2 or 3, wherein: In step (2), the amount of Ir[dF(CF3)ppy]2(dtbbpy)PF6 used is 0.0075 mmol relative to 0.50 mmol of the compound represented by formula (I-4).
6. The method according to claim 2 or 3, wherein: In step (2), the amount of NHC used is 0.80 mmol relative to 0.50 mmol of the compound represented by formula (I-4).
7. The method according to claim 2 or 3, wherein: In step (3), the amount of quinuclidine used is 0.60 mmol relative to 0.50 mmol of the compound represented by formula (I-4).
8. The method according to claim 2 or 3, wherein: In step (3), the conditions of the second reaction at least meet the following requirements: sealing, temperature of 0° C., irradiation with blue LED light, and stirring time of 36 h.
9. The method according to claim 2 or 3, wherein: The dosage ratio of the compound represented by formula (I-4) to the compound represented by formula (I-3) is 1:1.
6.
10. A chiral α-aryl amide compound prepared by the method according to any one of claims 2 to 9.
Citation Information
Patent Citations
Method for the organocatalytic activation of carboxylic acids for chemical reactions using orthosubstituted arylboronic acids
CN101861325A
Method for preparing chiral beta-aryl ketone compound through visible light / nickel catalyzed asymmetric beta-arylation reaction
CN114456207A
Enantioselective resolution process for arylpropionic acid drugs from the racemic mixture
US6093830A
